Claudin 18.2-CAR-T cell therapy

Drug Profile

Claudin 18.2-CAR-T cell therapy

Alternative Names: Anti-Claudin18.2-CAR-T cell therapy - CARsgen; CAR-CLD18 T cell therapy - CARsgen; Claudin18.2-redirected Autologous Cells - CARsgen; CLD18-CAR-T cell therapy - CARsgen

Latest Information Update: 11 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CARsgen
  • Developer CARsgen; Changhai Hospital of Shanghai
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Claudin 18 protein modulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastric cancer; Pancreatic cancer

Most Recent Events

  • 05 Oct 2017 Carsgen plans a phase I trial for Claudin 18.2-CAR-T cell therapy for Pancreatic cancer and Gastric cancer (In adults, In the elderly) in China (NCT03302403)
  • 10 Aug 2017 Phase-I clinical trials in Gastric cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV)
  • 10 Aug 2017 Phase-I clinical trials in Pancreatic cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top